Search

News Invitation to June: ESMO Gastrointestinal Cancers Congress 2024, Munich

Source: Treatment of Gastrointestinal Carcinomas 31. 5. 2024

News Smaller Volume and Faster Infusion Rate of aPCC: What Do Current Data Say About This Modification?

Administering an infusion of activated prothrombin complex concentrate (aPCC) at the standardized rate of 2 U/kg/min can be time-consuming, especially when repeated applications are needed. The authors of the recently published multicenter study cited below focused on the safety and tolerability of reducing the infusion volume by 50% and increasing the infusion rate to 4 and 10 U/kg/min.

Source: Hemophilia 6. 10. 2024

News Repeated Episodes of Respiratory Failure Due to Undiagnosed AAT Deficiency –⁠ Case Report

The case report from authors in Naples shows that alpha-1-antitrypsin deficiency (AATD) should be considered when respiratory symptoms occur at any age. It also illustrates the diagnostic procedure in such cases and confirms the effectiveness of subsequently initiated therapy.

Source: Deficiency of Alpha-1-Antitrypsin 14. 11. 2022

News Comparison of Dabigatran and Vitamin K Antagonists in Patients with Atrial Fibrillation in Real-World Practice

The final 3-year results of the GLORIA-AF study conducted in real-world practice with patients newly diagnosed with atrial fibrillation show a lower incidence of major bleeding and lower overall mortality with comparably effective prevention of cerebrovascular accidents and myocardial infarction when administering dabigatran compared to vitamin K antagonists (VKAs).

Source: Anticoagulant Treatment 21. 6. 2022

News Effectiveness of the Venetoclax/Rituximab Combination in the Treatment of CLL –⁠ 5-Year Follow-Up Data

At the virtual 62nd Annual Meeting of the American Society of Hematology (ASH), updated results of a clinical evaluation of the treatment of patients with refractory/relapsed chronic lymphocytic leukemia (R/R CLL) using venetoclax in combination with rituximab were presented.

Source: Chronic Lymphocytic Leukemia 12. 4. 2021

News Effectiveness of Idarucizumab Reversal Effect

It is, of course, a great advantage if doctors have a specific substance available that counteracts the effect of oral anticoagulants in urgent need. Idarucizumab is a humanized monoclonal antibody that binds dabigatran with high affinity. The drug was approved for clinical use based on an interim analysis of the results of 90 patients enrolled in the RE-VERSE AD study. What conclusions were drawn based on the results of the entire study population?

Source: Anticoagulant Treatment 21. 4. 2022

News Reverse Remodeling of LV in Patients with Diabetes/Prediabetes and Heart Failure with Reduced Ejection Fraction Treated with Empagliflozin

Authors of the British study SUGAR-DM-HF published in February 2021 examined whether empagliflozin reduces left ventricle (LV) volume in patients with type 2 diabetes mellitus (DM), prediabetes, and heart failure with reduced ejection fraction (EF). This favorable reverse remodeling of the LV could be a mechanism through which empagliflozin achieves reduced hospitalization rates for heart failure and overall mortality in these patients.

Source: Heart Failure 14. 1. 2022

News Factors Predicting Longer Survival in Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil

A recently published non-interventional analysis evaluated overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) with favorable prognostic factors before initiating treatment with trifluridine/tipiracil compared to patients with unfavorable factors. It also identified which specific prognostic factors are favorable in terms of therapy effectiveness.

Source: Treatment of Gastrointestinal Carcinomas 14. 12. 2022

News What can we base the decision on for the choice of initial treatment modality for CLL?

We now have a range of highly effective treatment options for patients with chronic lymphocytic leukemia (CLL). New drugs have significantly contributed to improved overall survival (OS). However, there are still questions about the most appropriate treatment regimen or criteria for choosing the initial therapeutic modality. Some of these questions are posed—and answers sought—by Professor John F. Seymour from the University of Melbourne in his recent communication.

Source: Chronic Lymphocytic Leukemia 18. 5. 2022

News When Size Matters or What Is Small Is Effective

The systemic effect of an orally administered drug can be expected, among other things, if it has suitable physicochemical properties. How can insufficient absorption or poor solubility be solved? We provide the answer below.

Source: Venous Insufficiency 28. 5. 2020

News Insufficient dosing of enoxaparin is common in patients post-orthopedic surgery and increases the risk of thromboembolic disease

Orthopedic and traumatological procedures involving the pelvis and lower limbs are associated with a significant increase in the risk of thromboembolic disease. Therefore, prophylaxis with anticoagulants is recommended in the perioperative and postoperative period for these procedures. The most commonly administered anticoagulants are low molecular weight heparins, among which enoxaparin is included. A recently published study by authors from the University of Utah focused on insufficient dosing of enoxaparin and its impact on the development of thromboembolic disease within 90 days following the procedure.

Source: Thromboprophylaxis 17. 3. 2020

News Presence of Risk Factors Associated with Colectomy in Patients with Ulcerative Colitis in Studies with Tofacitinib

One of the important goals of active ulcerative colitis therapy is the prevention of colectomy. A clinical study, the results of which were recently presented at the Vienna UEG (United European Gastroenterology) congress, evaluated the association of risk factors and the use of tofacitinib with colectomy in patients with active ulcerative colitis in the OCTAVE clinical trial program.

Source: Intestinal Inflammations 4. 12. 2022

News Need for Early Intervention in COPD −⁠ A Suitable Time for Mucolytic Treatment

Chronic Obstructive Pulmonary Disease (COPD) ranks third among the leading causes of morbidity and mortality worldwide, with more than 210 million people expected to be affected by 2030. While common, it is preventable and treatable. The mucolytic erdosteine has proven to be an effective helper in COPD therapy.

Source: Cough Therapy 24. 5. 2022

News Critical Overview of Clinical Studies on EHL FVIII Preparations

An international team of experts recently published a comprehensive work evaluating the methodology used in clinical trials of various extended half-life (EHL) factor VIII (FVIII) products. Their work does not directly compare the individual products but aims to assess the results of key registration clinical trials from the perspective of the hematologist and everyday clinical practice.

Source: Hemophilia 1. 2. 2023

News Role and Possibilities of Telemedicine in the Management of Hemophilia Care

A team of Irish experts recently evaluated the current possibilities of telemedicine in the care of individuals with hemophilia –⁠ not only from the perspective of care provided by specialized comprehensive centers but also considering physiotherapy and dental care.

Source: Hemophilia with Movement 22. 4. 2021